Rifampin’s promise against joint implant infections comes with sharp limits

Rifampin has long held a special place in the fight against infection around artificial joints, but a new narrative review argues that its role is far more conditional than its reputation suggests. Writing in the journal Arthroplasty, researchers led by Xijiu Zhao and Changjiao Sun summarize the clinical and laboratory evidence on rifampin in periprosthetic joint infection, or PJI, a severe complication of total joint replacement in which bacteria persist within biofilms on the prosthetic surface. The review concludes that rifampin should be used as a targeted adjunct rather than a universal standard, with its value depending on the surgical strategy, the pathogen, the timing of treatment, and the patient’s ability to tolerate the drug.

The central problem is the biofilm itself. Bacteria on an implant embed themselves in a self-produced matrix of extracellular polymeric substance, and within its deeper layers they can enter a metabolically dormant state. Conventional antibiotics such as beta-lactams, which kill actively dividing cells by blocking cell-wall synthesis, lose their bactericidal activity against these slow-growing or non-dividing organisms. This phenomenon, known as antibiotic tolerance, means that even prolonged intravenous therapy may fail to sterilize the infection and relapse rates can be high once treatment stops. Eradication therefore requires surgery for source control, ranging from debridement with implant retention, known as DAIR, to one-stage or two-stage revision arthroplasty, combined with antibiotics that can penetrate the biofilm.

Rifampin is unusual among those agents. It binds the beta-subunit of bacterial DNA-dependent RNA polymerase, the enzyme encoded by the rpoB gene, and blocks the initiation of RNA transcription, a process essential to cellular viability even in semi-dormant bacteria. That mechanism preserves its bactericidal activity against slowly growing organisms deep within the biofilm. Pharmacologically, the drug is highly lipophilic, with a volume of distribution of 0.8 to 1.6 liters per kilogram, and it penetrates bone, synovial fluid, and the biofilm matrix. Its oral bioavailability of 60 to 80 percent allows an easy switch from intravenous to outpatient treatment, an important consideration given the three to six months of therapy that PJI often demands. Unlike vancomycin, linezolid, or trimethoprim-sulfamethoxazole used alone, rifampin can reduce bacteria in both the bone and on the implant surface simultaneously.

The strongest clinical support comes from staphylococcal infections treated with two-stage revision. In an international multicenter observational cohort of 375 staphylococcal PJI cases, including 124 one-stage and 251 two-stage procedures, the failure rate in chronic PJI treated with two-stage revision was significantly lower among rifampin-treated patients than among those who did not receive the drug, 15 percent versus 35.5 percent. A pooled analysis of clinical evidence found an odds ratio of 2.68 for rifampin combination regimens compared with monotherapies or other combinations, and guidelines from the Infectious Diseases Society of America and the International Consensus Meeting on Orthopaedic Infection currently treat rifampin-combination therapy as the standard of care for staphylococcal PJI, most often paired with a fluoroquinolone.

The picture after DAIR is far less settled. The landmark randomized trial by Zimmerli and colleagues in 1998 reported a 100 percent cure rate with ciprofloxacin plus rifampin, compared with 58 percent cured on ciprofloxacin alone. But a more recent retrospective cohort of 227 patients with staphylococcal PJI who underwent DAIR or revision surgery found no statistically significant difference in remission rates, 78.48 percent versus 67.57 percent, while adverse events were significantly more frequent with rifampin, 31.65 percent versus 8.78 percent. Meta-analyses have added to the confusion: one found only a modest association between rifampin and treatment success after DAIR, a pooled relative risk of 1.10, with the authors flagging confounding, selection bias, and publication bias, while another reported an odds ratio of 2.49 for success with rifampin-containing regimens that lost statistical significance when restricted to randomized controlled trials. In non-staphylococcal infections, the evidence is pathogen-dependent: a multicenter study of 462 patients treated with DAIR alone suggested a benefit of early rifampin in streptococcal PJI, whereas in 187 Cutibacterium PJI cases the addition of rifampin produced only tentative, non-significant reductions in failure and relapse, with prolonged antibiotic therapy and surgical strategy mattering more.

Tolerability is a persistent obstacle. In patients with PJI, as many as 91 percent develop gastrointestinal disturbances such as nausea, vomiting, and significant abdominal discomfort, with dose reductions needed in about 29 percent of those cases. Rifampin can also cause transient rises in liver transaminases and, rarely, clinical hepatitis, requiring continuous monitoring of liver function throughout treatment. Interruption carries a steep price: Mayo Clinic data show that stopping rifampin because of intolerance or drug interactions increases the rate of PJI treatment failure 3.5-fold. The drug is also one of the most potent inducers of the hepatic cytochrome P450 system, particularly the CYP3A4, CYP2C9, and CYP2C19 enzymes, accelerating the metabolism of many co-administered medications. About 18.4 percent of PJI patients are absolutely contraindicated for systemic rifampin because of severe or unmanageable interactions, and even among patients who meet IDSA criteria for the drug, nearly half cannot start it because of pre-existing hepatic or renal impairment or indispensable medications such as warfarin or direct oral anticoagulants. Rifampin also lowers plasma concentrations of companion antibiotics including doxycycline, trimethoprim-sulfamethoxazole, clindamycin, and fusidic acid, raising the risk of both treatment failure and resistance. For patients who cannot take rifampin, the derivatives rifabutin and rifapentine offer alternatives, with rifabutin showing a markedly lower drug-interaction rate of 3.4 percent and, in vitro, lower minimum biofilm eradication concentrations against staphylococci, though their activity against streptococcal and enterococcal biofilms is limited.

Resistance compounds the difficulty. Because rifampin inhibits a single bacterial enzyme, high-level resistance can emerge rapidly from point mutations in rpoB, which is why the drug must never be used alone. In a Swedish single-center cohort of 238 patients with staphylococcal PJI, rifampin-resistant strains appeared in 17 percent of cases, and two-year infection-free survival fell from 90.0 percent in the rifampin-sensitive group to 78.6 percent among those infected with resistant strains, with a hazard ratio of 4.2 for treatment failure. The stakes are especially high after DAIR: among 81 patients with early PJI treated with debridement and retention, the reinfection rate reached 80 percent after the first procedure and 70 percent after repeat debridement in patients harboring rifampin-resistant staphylococci, and the adjusted odds of relapse were roughly four times higher than in patients with sensitive strains.

Timing adds another layer of complexity. In a multicenter observational study of 669 patients with acute staphylococcal PJI treated with DAIR, rifampin use was associated with treatment success overall, but initiation within five days after debridement was independently associated with treatment failure, with an odds ratio of 1.96. DAIR performed within one week of symptom onset was linked to significantly higher eradication rates, suggesting that timely surgery is a prerequisite for adjunctive rifampin to work. After two-stage exchange, by contrast, early initiation appears feasible: in a retrospective study of 212 patients, rifampin-based therapy started by postoperative day 2 was associated with low rates of acquired resistance during follow-up. The choice of companion antibiotic matters as well. A meta-analysis of 27 studies found a statistically significant improvement in cure rates only when rifampin was paired with fluoroquinolones, largely because rifampin’s enzyme induction reduces plasma levels of linezolid, clindamycin, and cotrimoxazole while fluoroquinolone concentrations remain relatively stable. Yet fluoroquinolone resistance is spreading, with ciprofloxacin-resistant MRSA strains reported at rates of 66.7 to 100 percent in some cohorts, and the meta-analysis pooled PJI with spinal and fracture-related infections, limiting how far its conclusions can be applied to prosthetic joints.

The review also examines why rifampin cannot simply be mixed into the antibiotic-loaded bone cement used in spacers. PMMA polymerization is an exothermic radical chain reaction driven by the initiator dibenzoyl peroxide and the accelerator dimethyl-p-toluidine, but rifampin contains a hydroquinone moiety that acts as a potent free-radical scavenger, competing with the initiators and terminating the polymerization chain. The result is a setting time exceeding one hour, incomplete polymerization, reduced compressive strength, and pathological surface porosity. Reducing the dose does not solve the problem: 300 milligrams still delayed curing by 20 minutes, and even 100 milligrams per 40 grams of cement reduced mechanical strength. Worse, rifampin trapped in the cement matrix largely fails to elute, producing local concentrations below the minimum inhibitory concentration that not only fail to kill biofilm but select for resistant mutants.

Bioengineering may offer a way around this chemical conflict. Microencapsulated rifampin formulations have preserved PMMA curing characteristics and mechanical properties in preclinical work, with animal studies showing sustained local drug release and antimicrobial activity, and mesoporous silica nanoparticles have improved both cement mechanics and drug release compared with direct mixing. The authors are careful to note that these approaches remain at the proof-of-concept stage, with industrial-scale manufacturing, sterilization stability, and long-term in vivo safety still unproven, and they call for validation in large-animal models and safety-focused clinical trials. Until then, their conclusion stands: rifampin remains an important component of therapy for selected staphylococcal implant infections, but only when paired with the right surgery, the right partner drug, the right timing, and a patient who can tolerate it.

Subject of Research: The role of rifampin in managing periprosthetic joint infections

Article Title: The role, challenges, and innovations of rifampin in the management of periprosthetic joint infections: a narrative review

Article References: Zhao, X., Li, T., Ma, Q., Lou, J., Cai, X., & Sun, C. (2026). The role, challenges, and innovations of rifampin in the management of periprosthetic joint infections: a narrative review. Arthroplasty, 8(1), Article 83. https://doi.org/10.1186/s42836-026-00445-z

Image Credits: AI Generated

DOI: 10.1186/s42836-026-00445-z

Keywords: periprosthetic joint infection, rifampin, biofilm, DAIR, two-stage revision, antibiotic resistance, drug interactions, bone cement, microencapsulation, nanoparticles, staphylococcal infection, arthroplasty